



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LUAVPPOSI
(Cycles 1 to 4)

Page 1 of 2

DOCTOR'S ORDERS		Ht _____ cm Wt _____ kg BSA _____ m ²						
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form								
DATE:	To be given:	Cycle #:						
Date of Previous Cycle: _____								
<input type="checkbox"/> Delay treatment _____ week(s)								
<input type="checkbox"/> CBC & Diff day of treatment								
May proceed with doses as written if within 96 hours ANC greater than or equal to $1.5 \times 10^9/L$, platelets greater than or equal to $100 \times 10^9/L$, and creatinine clearance greater than or equal to 45mL/minute (for pemetrexed and CARBOplatin), or greater than or equal to 60 mL/minute (for CISplatin)								
Dose modification for: <input type="checkbox"/> Hematology <input type="checkbox"/> Other Toxicity: _____								
Proceed with treatment based on blood work from _____								
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____.								
dexamethasone <input type="checkbox"/> 8 mg or <input type="checkbox"/> 12 mg (select one) PO 30 to 60 minutes prior to treatment								
AND select ONE of the following:	<table border="1" style="width: 100%; border-collapse: collapse;"><tr><td style="width: 30px; text-align: center;"><input type="checkbox"/></td><td>aprepitant 125 mg PO 30 to 60 minutes prior to treatment, and ondansetron 8 mg PO 30 to 60 minutes prior to treatment</td></tr><tr><td style="text-align: center;"><input type="checkbox"/></td><td>netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to treatment</td></tr><tr><td style="text-align: center;"><input type="checkbox"/></td><td>ondansetron 8 mg PO 30 to 60 minutes prior to treatment</td></tr></table>		<input type="checkbox"/>	aprepitant 125 mg PO 30 to 60 minutes prior to treatment, and ondansetron 8 mg PO 30 to 60 minutes prior to treatment	<input type="checkbox"/>	netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to treatment	<input type="checkbox"/>	ondansetron 8 mg PO 30 to 60 minutes prior to treatment
<input type="checkbox"/>	aprepitant 125 mg PO 30 to 60 minutes prior to treatment, and ondansetron 8 mg PO 30 to 60 minutes prior to treatment							
<input type="checkbox"/>	netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to treatment							
<input type="checkbox"/>	ondansetron 8 mg PO 30 to 60 minutes prior to treatment							
If additional antiemetic required:								
<input type="checkbox"/> OLANzapine <input type="checkbox"/> 2.5 mg or <input type="checkbox"/> 5 mg or <input type="checkbox"/> 10 mg (select one) PO 30 to 60 minutes prior to treatment								
Ensure patient is taking folic acid and has had vitamin B12 injection starting at least 7 days prior to first cycle, and to continue while on treatment, until 21 days after last pemetrexed dose.								
<input type="checkbox"/> Other: _____								
Have Hypersensitivity Reaction Tray & Protocol Available								
HYDRATION:								
1000 mL NS over 1 hour prior to CISplatin								
Continued on page 2								
DOCTOR'S SIGNATURE:		SIGNATURE:						
		UC:						



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LUAVPPOSI
(Cycles 1 to 4)

Page 2 of 2

DATE:

TREATMENT:

pemetrexed 500 mg/m² x BSA = _____ mg

☐ Dose Modification: _____ % = _____ mg/m² x BSA = _____ mg

IV in 100 mL NS over 10 minutes (may be given during prehydration)

Select one:

☐ **CISplatin 75 mg/m² x BSA = _____ mg**

☐ Dose Modification: _____ % = _____ mg/m² x BSA = _____ mg

IV in 500 mL NS, with potassium chloride 20 mEq, magnesium sulphate 1 g and mannitol 30 g over 1 hour

OR

☐ **CARBOplatin AUC 5 x (GFR + 25) = _____ mg**

☐ Dose Modification: _____ % = _____ mg

IV in 100 to 250 mL NS over 30 minutes

osimertinib 80 mg PO once daily

☐ Dose modification: **osimertinib 40 mg PO once daily**

Supply for: _____ days (maximum 90 days)

RETURN APPOINTMENT ORDERS

☐ Return in **three** weeks for Doctor and Cycle _____

☐ Last Cycle. Return in _____ week(s)

CBC & Diff, creatinine, alkaline phosphatase, ALT, total bilirubin, LDH, sodium, potassium, calcium, magnesium prior to each treatment

Vitamin B12 injection required every 9 weeks. Patient to obtain supply.

☐ This patient to receive injection in clinic. Next injection due by _____.

If clinically indicated: ☐ **ECG** ☐ **Chest X-ray** ☐ **CT scan (chest)**

☐ **MUGA scan** or ☐ **echocardiogram** (select one)

☐ **Other tests:**

☐ **Consults:**

☐ **See general orders sheet for additional requests.**

DOCTOR'S SIGNATURE:

SIGNATURE:

UC: